메뉴 건너뛰기




Volumn 380, Issue 9856, 2012, Pages 1795-1797

Alemtuzumab for multiple sclerosis: Who and when to treat?

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON;

EID: 84869498358     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61859-5     Document Type: Note
Times cited : (4)

References (16)
  • 2
    • 84855964379 scopus 로고    scopus 로고
    • Multiple sclerosis: New insights in pathogenesis and novel therapeutics
    • Ontaneda D, Hyland M, Cohen JA. Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med 2012; 63: 389-404.
    • (2012) Annu Rev Med , vol.63 , pp. 389-404
    • Ontaneda, D.1    Hyland, M.2    Cohen, J.A.3
  • 4
    • 84857055778 scopus 로고    scopus 로고
    • Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
    • Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 298-304.
    • (2012) J Neurol Neurosurg Psychiatry , vol.83 , pp. 298-304
    • Hill-Cawthorne, G.A.1    Button, T.2    Tuohy, O.3
  • 5
    • 0030177999 scopus 로고    scopus 로고
    • CAMPATH-IH in multiple sclerosis
    • Moreau T, Coles A, Wing M, et al. CAMPATH-IH in multiple sclerosis. Mult Scler 1996; 1: 357-65.
    • (1996) Mult Scler , vol.1 , pp. 357-365
    • Moreau, T.1    Coles, A.2    Wing, M.3
  • 6
    • 54949143968 scopus 로고    scopus 로고
    • Alemtuzumab vs interferon beta-1a in early multiple sclerosis
    • Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-801.
    • (2008) N Engl J Med , vol.359 , pp. 1786-1801
    • Coles, A.J.1    Compston, D.A.2    Selmaj, K.W.3
  • 7
    • 80053207130 scopus 로고    scopus 로고
    • Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
    • Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011; 77: 573-79.
    • (2011) Neurology , vol.77 , pp. 573-579
    • Cossburn, M.1    Pace, A.A.2    Jones, J.3
  • 8
    • 84869492471 scopus 로고    scopus 로고
    • Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial
    • for the CARE-MS I investigators; published online Nov 1
    • Cohen JA, Coles AJ, Arnold DL, et al, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; published online Nov 1. http://dx.doi.org/10.1016/S0140-6736(12) 61769-3.
    • (2012) Lancet
    • Cohen, J.A.1    Coles, A.J.2    Arnold, D.L.3
  • 9
    • 84869507357 scopus 로고    scopus 로고
    • Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial
    • for the CARE-MS II investigators; published online Nov 1
    • Coles AJ, Twyman CL, Arnold DL, et al, for the CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; published online Nov 1. http://dx.doi.org/10.1016/S0140-6736(12)61768-1.
    • (2012) Lancet
    • Coles, A.J.1    Twyman, C.L.2    Arnold, D.L.3
  • 10
    • 8844285856 scopus 로고    scopus 로고
    • Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials
    • Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63: 1779-87.
    • (2004) Neurology , vol.63 , pp. 1779-1787
    • Kappos, L.1    Weinshenker, B.2    Pozzilli, C.3
  • 11
    • 33644608613 scopus 로고    scopus 로고
    • Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    • Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23.
    • (2006) N Engl J Med , vol.354 , pp. 911-923
    • Rudick, R.A.1    Stuart, W.H.2    Calabresi, P.A.3
  • 12
    • 76149140914 scopus 로고    scopus 로고
    • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    • Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
    • (2010) N Engl J Med , vol.362 , pp. 402-415
    • Cohen, J.A.1    Barkhof, F.2    Comi, G.3
  • 13
    • 84861040663 scopus 로고    scopus 로고
    • Predicting risk of progressive multifocal leukoencephalopathy from natalizumab
    • Ropper AH. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab. N Engl J Med 2012; 366: 1938-39.
    • (2012) N Engl J Med , vol.366 , pp. 1938-1939
    • Ropper, A.H.1
  • 14
    • 79960344014 scopus 로고    scopus 로고
    • Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring
    • Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10: 745-58.
    • (2011) Lancet Neurol , vol.10 , pp. 745-758
    • Kappos, L.1    Bates, D.2    Edan, G.3
  • 15
    • 68849084141 scopus 로고    scopus 로고
    • IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
    • Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119: 2052-61.
    • (2009) J Clin Invest , vol.119 , pp. 2052-2061
    • Jones, J.L.1    Phuah, C.L.2    Cox, A.L.3
  • 16
    • 84860780657 scopus 로고    scopus 로고
    • Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial
    • Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78: 1069-78.
    • (2012) Neurology , vol.78 , pp. 1069-1078
    • Coles, A.J.1    Fox, E.2    Vladic, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.